Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.59 |
| ▸ | MET | P08581 | 13/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
| ▸ | MERTK | Q12866 | 2/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882755 | 0.94 | MET (0.56) | AXLMETKDRMERTK | |
| SCHEMBL4887103 | 0.91 | AXL (0.62) | AXLMETKDRRIPK2RIPK1 | |
| SCHEMBL4884069 | 0.88 | MET (0.52) | AXLMETKDR | |
| SCHEMBL4887090 | 0.87 | KDR (0.54) | AXLMETKDR | |
| SCHEMBL4889760 | 0.87 | AXL (0.59) | AXLMETKDRRIPK2RIPK1 | |
| SCHEMBL4888377 | 0.85 | AXL (0.49) | AXLMETKDR | |
| SCHEMBL4728517 | 0.85 | MET (0.62) | AXLMETKDR | |
| SCHEMBL4846666 | 0.83 | AXL (0.61) | AXLMETKDRRIPK2RIPK1 | |
| SCHEMBL4330366 | 0.83 | MET (0.65) | AXLMETKDRRIPK2RIPK1 | |
| SCHEMBL3613361 | 0.81 | MET (0.62) | AXLMETKDRRIPK2RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | AXL 475/4885MET 545/4885KDR 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.